Phase Ib/II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastases.

Trial Profile

Phase Ib/II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastases.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Liver metastases; Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SECIRA-UM
  • Most Recent Events

    • 07 Oct 2016 Status changed from recruiting to completed.
    • 12 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top